drugset / Trial / NCT01521455

Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients

NCT01521455

Phase 1 Completed 56 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to prove that HCP0910 is therapeutically equivalent to Seretide 250 Diskus when repeatedly dosed to Asthmatic patients.

Timeline

Start
2012-02
Primary completion
2013-06
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified 250 ug
Subject Salmeterol Other / unclassified 50 ug
Comparator Seretide Diskus Unknown

Indications